Journals / Annals of Medical Sciences / 2001 / Cilt: 10 - Sayı: 1

P-53 and H-ras mutations in lung cancer patients 40 years of age and younger and its correlation to tumor stage and Ki-67 immunostaining: A preliminary report

Pages
32–36
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although p53 and H-ras gene mutations do not play a specific role in young adults on lung carcinogenesis compared to older patients our preliminary results show that, p53 overexpression and absence of H-ras expression in these tumors might be associated with aggressive biological behavior.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To define the roles of the p53 and H-ras gene mutations in the development and biological behavior of lung cancer specifically in young adults.
📊
Key Findings & Data:Methods: The archival tumor tissues of 19 patients 40 years of age or younger were studied by means of immunohistochemistry and compared to the tissues of randomly selected 15 patients older than 40 years.
💡
Conclusion & Impact:Conclusion: Although p53 and H-ras gene mutations do not play a specific role in young adults on lung carcinogenesis compared to older patients our preliminary results show that, p53 overexpression and absence of H-ras expression in these tumors might be associated with aggressive biological behavior.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To define the roles of the p53 and H-ras gene mutations in the development and biological behavior of lung cancer specifically in young adults. Methods: The archival tumor tissues of 19 patients 40 years of age or younger were studied by means of immunohistochemistry and compared to the tissues of randomly selected 15 patients older than 40 years. Results: In the younger group, p53 and H-ras mutations were found in 11 patients (57.9%) and 4 patients (21.1%), respectively. In the older group, 10 patients (66.6%) showed p53 mutations, whereas none of the cases showed H-ras mutations. Neither p53 nor H-ras immunoreactivity showed statistical significance with age, sex, histologic type, stage and proliferative activity assessed by Ki-67 expression. However, in multivariate analysis, p53 immunopositive and H-ras immunonegative tumors showed significant relation with advanced tumor stage and stronger Ki-67 immunoreactivity. Conclusion: Although p53 and H-ras gene mutations do not play a specific role in young adults on lung carcinogenesis compared to older patients our preliminary results show that, p53 overexpression and absence of H-ras expression in these tumors might be associated with aggressive biological behavior.

🔖

Cite This Article

ÖZER, E., ÖZKAL, S., KARGI, A., SAĞOL, Ö., ERMETE, S., TATAR, D., YÖRÜKOĞLU, K. (2022). P-53 and H-ras mutations in lung cancer patients 40 years of age and younger and its correlation to tumor stage and Ki-67 immunostaining: A preliminary report. Annals of Medical Sciences, Cilt: 10 - Sayı: 1, 32–36. https://ajindex.com/articles/447468

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Levesque MA, D'Costa M, Spratt EH,et al. Quantitative analysis of p53 protein in non-small cell lung cancer and its prognostic value. Int J Cancer, 1998
  2. Takagi Y, Osada H., Kuroishi T,et al. p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br J Cancer, 1998
  3. Tagawa M, Murata M, Kimura H. Prognostic value of mutations and a germ line polymorphism of the p53 gene in non-small cell lung carcinoma: association with clini-copathological features. Cancer Lett, 1998
  4. Rodenhuis S., Slebos RJ. The ras oncogenes in human lung cancer. Am Rev Respir Dis, 1990
  5. Rusch VW, Reuter VE, Kris MG,et al. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. J Thorac Cardiovasc Surg, 1992
  6. , 6.Greatens TM, Niehans GA, Rubins JB, et al. Do molecu-lar markers predict survival in non-small-cell lung can-cer? Am J Respir Crit Care Med, 1998
  7. Esposito V, Baldi A, De Luca A,et al. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum Pathol, 1997
  8. Sekine I, Yokose T, Ogura T, et al. Microsatellite insta-bility in lung cancer patients 40 years of age or younger. Jpn J Cancer Res, 1997
  9. Wingo PA, Ries LA, Parker SL, et al. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev, 1998
  10. Nugent WC, Edney MT, Hammerness PG, et al. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg, 1997
  11. de Rijke JM, Schouten LJ, Schouten HC, et al. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann Oncol, 1996
  12. Brown JS, Eraut D, Trask C, et al. Age and the treatment of lung cancer. Thorax, 1996
  13. Weston A., Caporasoi NE, Perrin LS, et al. Relationship of H-ras-1, L-myc, and p53 polymorphisms with lung cancer risk and prognosis. Environ Health Perspect, 1992
  14. Mountain CF.A new international staging system for lung cancer. Chest, 1986
  15. Taylor CR, Cote RJ. Immunomicroscopy: A diagnostic tool for the surgical pathologist, 2 nd ed.WB Saunders Company, Philadelphia, 1994:417-419. 16.Gilcrease M.Z, Truong L, Brown RW. Correlation of very late activation